Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% Return-on-Tangible-Asset is 3.62% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 213 Medical Diagnostics & Research companies, Invitro International ranks better than 70.89% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Invitro International's annualizedNet Income for the quarter that ended in Mar. 2026 was $0.07 Mil. Invitro International's average total tangible assets for the quarter that ended in Mar. 2026 was $1.99 Mil. Therefore, Invitro International's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 3.62%.
The historical rank and industry rank for Invitro International's Return-on-Tangible-Asset or its related term are showing as below:
IVRO'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -226.67 Med: -57.73 Max: 6.45
Current: 5.05
During the past 9 years, Invitro International's highest Return-on-Tangible-Asset was 6.45%. The lowest was -226.67%. And the median was -57.73%.
IVRO's Return-on-Tangible-Asset is ranked better than 70.89% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs IVRO: 5.05
Invitro International (OTCPK:IVRO) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Invitro International Return-on-Tangible-Asset Related Terms
Invitro International Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Invitro International's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invitro International Return-on-Tangible-Asset Chart
IVRO vs IDTA, PRPH, NSTM: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Invitro International's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Invitro International's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 3.62% mean?
Invitro International (IVRO) has a Return-on-Tangible-Asset of 3.62% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Invitro International and its competitors. According to the industry distribution chart, Invitro International ranks #62 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 29.1%.
Is Invitro International's Return-on-Tangible-Asset too high?
Invitro International's current Return-on-Tangible-Asset is 3.62%. Based on the distribution chart, Invitro International ranks #62 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Invitro International's Return-on-Tangible-Asset compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #62 out of 213 companies for Return-on-Tangible-Asset. This puts Invitro International in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Invitro International and its competitors. Invitro International's current Return-on-Tangible-Asset is 3.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current Return-on-Tangible-Asset is 3.62%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Invitro International (IVRO), the current Return-on-Tangible-Asset is 3.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
